These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 36496381)

  • 1. Synergistic combination of targeted nano-nuclear-reactors and anti-PD-L1 nanobodies evokes persistent T cell immune activation for cancer immunotherapy.
    Zhu L; Li J; Guo Z; Kwok HF; Zhao Q
    J Nanobiotechnology; 2022 Dec; 20(1):521. PubMed ID: 36496381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells.
    Xu HZ; Li TF; Wang C; Ma Y; Liu Y; Zheng MY; Liu ZJ; Chen JB; Li K; Sun SK; Komatsu N; Xu YH; Zhao L; Chen X
    J Nanobiotechnology; 2021 Sep; 19(1):268. PubMed ID: 34488792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression.
    Kim M; Lee JS; Kim W; Lee JH; Jun BH; Kim KS; Kim DE
    J Control Release; 2022 Aug; 348():893-910. PubMed ID: 35760233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
    Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering Endogenous Tumor-Associated Macrophage-Targeted Biomimetic Nano-RBC to Reprogram Tumor Immunosuppressive Microenvironment for Enhanced Chemo-Immunotherapy.
    Wang Y; Yu J; Luo Z; Shi Q; Liu G; Wu F; Wang Z; Huang Y; Zhou D
    Adv Mater; 2021 Oct; 33(39):e2103497. PubMed ID: 34387375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Charge reversal yolk-shell liposome co-loaded JQ1 and doxorubicin with high drug loading and optimal ratio for synergistically enhanced tumor chemo-immunotherapy via blockade PD-L1 pathway.
    Liu D; Li K; Gong L; Fu L; Yang D
    Int J Pharm; 2023 Mar; 635():122728. PubMed ID: 36796659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multifunctional Redox-Responsive Nanoplatform with Dual Activation of Macrophages and T Cells for Antitumor Immunotherapy.
    Zhang W; Liu X; Cao S; Zhang Q; Chen X; Luo W; Tan J; Xu X; Tian J; Saw PE; Luo B
    ACS Nano; 2023 Aug; 17(15):14424-14441. PubMed ID: 37498878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Size-optimized nuclear-targeting phototherapy enhances the type I interferon response for "cold" tumor immunotherapy.
    Zhang X; Yi C; Zhang L; Zhu X; He Y; Lu H; Li Y; Tang Y; Zhao W; Chen G; Wang C; Huang S; Ouyang G; Yu D
    Acta Biomater; 2023 Mar; 159():338-352. PubMed ID: 36669551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repolarizing Tumor-Associated Macrophages and inducing immunogenic cell Death: A targeted liposomal strategy to boost cancer immunotherapy.
    Li C; Wang L; Li Z; Li Z; Zhang K; Cao L; Wang Z; Shen C; Chen L
    Int J Pharm; 2024 Feb; 651():123729. PubMed ID: 38142016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast Activation Protein-α Responsive Peptide Assembling Prodrug Nanoparticles for Remodeling the Immunosuppressive Microenvironment and Boosting Cancer Immunotherapy.
    Sun M; Yao S; Fan L; Fang Z; Miao W; Hu Z; Wang Z
    Small; 2022 Mar; 18(9):e2106296. PubMed ID: 34914185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hybrid Cellular Nanovesicles Block PD-L1 Signal and Repolarize M2 Macrophages for Cancer Immunotherapy.
    Zhao C; Pan Y; Liu L; Zhang J; Wu X; Liu Y; Zhao XZ; Rao L
    Small; 2024 Aug; 20(31):e2311702. PubMed ID: 38456371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-delivery photodynamic-hypoxia alleviating nanomedicine synergizes with anti-PD-L1 for cancer immunotherapy.
    Feng X; Chen Z; Liu Z; Fu X; Song H; Zhang Q
    Int J Pharm; 2023 May; 639():122970. PubMed ID: 37084832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Nanobody-Bioorthogonal Catalyst Conjugate Triggers Spatially Confined Prodrug Activation for Combinational Chemo-immunotherapy.
    Zhao Z; Wang X; Wang J; Li Y; Lin W; Lu K; Chen J; Xia W; Mao ZW
    J Med Chem; 2023 Sep; 66(17):11951-11964. PubMed ID: 37590921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated Nanorod-Mediated PD-L1 Downregulation in Combination with Oxidative-Stress Immunogene Therapy against Cancer.
    Wu S; Zhang J; Pan J; Bai S; Wang Z; Chen Y; Xu D; An Y; Liu C; Chu C; Dai Q; Jiang L; Lu Z; Liu G
    Adv Healthc Mater; 2023 Jul; 12(17):e2300110. PubMed ID: 36773310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanobodies in cell-mediated immunotherapy: On the road to fight cancer.
    Maali A; Gholizadeh M; Feghhi-Najafabadi S; Noei A; Seyed-Motahari SS; Mansoori S; Sharifzadeh Z
    Front Immunol; 2023; 14():1012841. PubMed ID: 36761751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing photodynamic immunotherapy by reprograming the immunosuppressive tumor microenvironment with hypoxia relief.
    He M; Zhang M; Xu T; Xue S; Li D; Zhao Y; Zhi F; Ding D
    J Control Release; 2024 Apr; 368():233-250. PubMed ID: 38395154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
    Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
    Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
    [No Abstract]   [Full Text] [Related]  

  • 19. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Charge-switchable nanoparticles enhance Cancer immunotherapy based on mitochondrial dynamic regulation and immunogenic cell death induction.
    Zhao M; Li J; Liu J; Xu M; Ji H; Wu S; Chen D; Hu H
    J Control Release; 2021 Jul; 335():320-332. PubMed ID: 34062192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.